السوق العالمية لأدوية السكري الفموية - اتجاهات الصناعة والتوقعات حتى عام 2029

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL ORAL ANTIDIABETIC DRUGS MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATION

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 KEY TAKEAWAYS

2.2 ARRIVING AT THE GLOBAL XX SIZE

2.2.1 VENDOR POSITIONING GRID

2.2.2 TECHNOLOGY LIFE LINE CURVE

2.2.3 TRIPOD DATA VALIDATION MODEL

2.2.4 MARKET GUIDE

2.2.5 MULTIVARIATE MODELLING

2.2.6 TOP TO BOTTOM ANALYSIS

2.2.7 CHALLENGE MATRIX

2.2.8 APPLICATION COVERAGE GRID

2.2.9 STANDARDS OF MEASUREMENT

2.2.10 VENDOR SHARE ANALYSIS

2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS

2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES

2.3 GLOBAL ORAL ANTIDIABETIC DRUGS MARKET: RESEARCH SNAPSHOT

2.4 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER’S FIVE FORCES MODEL

5 INDUSTRY INSIGHTS

5.1 PATENT ANALYSIS

5.1.1 PATENT LANDSCAPE

5.1.2 USPTO NUMBER

5.1.3 PATENT EXPIRY

5.1.4 EPIO NUMBER

5.1.5 PATENT STRENGTH AND QUALITY

5.1.6 PATENT CLAIMS

5.1.7 PATENT CITATIONS

5.1.8 PATENT LITIGATION AND LICENSING

5.1.9 FILE OF PATENT

5.1.10 PATENT RECEIVED CONTRIES

5.1.11 TECHNOLOGY BACKGROUND

5.2 DRUG TREATMENT RATE BY MATURED MARKETS

5.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES

5.4 PATIENT FLOW DIAGRAM

5.5 KEY PRICING STRATEGIES

5.6 KEY PATIENT ENROLLMENT STRATEGIES

5.7 INTERVIEWS WITH SPECIALIST

5.8 OTHER KOL SNAPSHOTS

6 EPIDEMIOLOGY

6.1 INCIDENCE OF ALL BY GENDER

6.2 TREATMENT RATE

6.3 MORTALITY RATE

6.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL

6.5 PATIENT TREATMENT SUCCESS RATES

6.6 TREATMENT PARADIGM AND OUTLOOK

7 MERGERS AND ACQUISITION

7.1 LICENSING

7.2 COMMERCIALIZATION AGREEMENTS

8 REGULATORY FRAMEWORK

8.1 REGULATORY APPROVAL PROCESS

8.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL

8.3 REGULATORY APPROVAL PATHWAYS

8.4 LICENSING AND REGISTRATION

8.5 POST-MARKETING SURVEILLANCE

8.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES

9 PIPELINE ANALYSIS

9.1 CLINICAL TRIALS AND PHASE ANALYSIS

9.2 DRUG THERAPY PIPELINE

9.3 PHASE III CANDIDATES

9.4 PHASE II CANDIDATES

9.5 PHASE I CANDIDATES

9.6 OTHERS (PRE-CLINICAL AND RESEARCH)

TABLE 1 GLOBAL CLINICAL TRIAL MARKET FOR XX

Company Name Therapeutic Area

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE

Phase Number of Projects

Preclinical/Research Projects XX

Clinical Development XX

Phase I XX

Phase II XX

Phase III XX

U.S. Filed/Approved But Not Yest Marketed XX

Total XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE

Therapeutic Area Preclinical/ Research Project

XX XX

XX XX

XX XX

XX XX

XX XX

Total Projects XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE

Technology Preclinical/ Research Project

XX XX

XX XX

XX XX

XX XX

XX XX

Total Projects XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE FOR XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

10 MARKETED DRUG ANALYSIS

10.1 DRUG

10.1.1 BRAND NAME

10.1.2 GENERICS NAME

10.2 THERAPEUTIC INDIACTION

10.3 PHARACOLOGICAL CLASS OD THE DRUG

10.4 DRUG PRIMARY INDICATION

10.5 MARKET STATUS

10.6 MEDICATION TYPE

10.7 DRUG DOSAGES FORM

10.8 DOSAGES AVAILABILITY

10.9 PACKAGING TYPE

10.1 DRUG ROUTE OF ADMINISTRATION

10.11 DOSING FREQUENCY

10.12 DRUG INSIGHT

10.13 AN OVERVIEW OF THE DRUG DEVELOPMENT ACTIVITIES SUCH AS REGULATORY MILSTONE, SAFETY DATA AND EFFICACY DATA, MARKET EXCLUSIVITY DATA.

10.13.1 FORECAST MARKET OUTLOOK

10.13.2 CROSS COMPETITION

10.13.3 THERAPEUTIC PORTFOLIO

10.13.4 CURRENT DEVELOPMENT SCENARIO

11 MARKET ACCESS

11.1 10-YEAR MARKET FORECAST

11.2 CLINICAL TRIAL RECENT UPDATES

11.3 ANNUAL NEW FDA APPROVED DRUGS

11.4 DRUGS MANUFACTURER AND DEALS

11.5 MAJOR DRUG UPTAKE

11.6 CURRENT TREATMENT PRACTICES

11.7 IMPACT OF UPCOMING THERAPY

12 R & D ANALYSIS

12.1 COMPARATIVE ANALYSIS

12.2 DRUG DEVELOPMENTAL LANDSCAPE

12.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES

12.4 THERAPEUTIC ASSESSMENT

12.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS

13 MARKET OVERVIEW

13.1 DRIVERS

13.2 RESTRAINTS

13.3 OPPORTUNITIES

13.4 CHALLENGES

14 GLOBAL ORAL ANTIDIABETIC DRUGS MARKET, BY DRUG CLASS

14.1 OVERVIEW

14.2 BIGUANIDES (METFORMIN)

14.2.1 BIGUANIDES (METFORMIN), BY TYPE

14.2.1.1. MONOTHERAPY

14.2.1.2. COMBINATION THERAPY

14.2.2 BIGUANIDES, BY DRUG TYPE

14.2.2.1. GENERIC

14.2.2.2. BRANDED

14.2.2.2.1. FORTAMET

14.2.2.2.2. GLUCOPHAGE

14.2.2.2.3. GLUCOPHAGE XR

14.2.2.2.4. GLUMETZA

14.2.2.2.5. RIOMET

14.2.2.2.6. OTHERS (IF ANY)

14.3 THIAZOLIDINEDIONES

14.3.1 THIAZOLIDINEDIONES, BY TYPE

14.3.1.1. ROSIGLITAZONE

14.3.1.2. PIOGLITAZONE

14.3.2 THIAZOLIDINEDIONES, BY DRUG TYPE

14.3.2.1. GENERIC

14.3.2.2. BRANDED

14.3.2.2.1. ACTOS

14.3.2.2.2. AVANDIA

14.3.2.2.3. OTHERS (IF ANY)

14.4 DIPEPTIDYL PEPTIDASE IV INHIBITORS

14.4.1 DIPEPTIDYL PEPTIDASE IV INHIBITORS, BY TYPE

14.4.1.1. SITAGLIPTIN

14.4.1.2. LINAGLIPTIN

14.4.1.3. SAXAGLIPTIN

14.4.1.4. ALOGLIPTIN

14.4.2 DIPEPTIDYL PEPTIDASE IV INHIBITORS, BY DRUG TYPE

14.4.2.1. GENERIC

14.4.2.2. BRANDED

14.4.2.2.1. JANUVIA

14.4.2.2.2. TRADJENTA

14.4.2.2.3. ONGLYZA

14.4.2.2.4. NESINA

14.4.2.2.5. OTHERS (IF ANY)

14.5 Α-GLUCOSIDASE INHIBITORS

14.5.1 A-GLUCOSIDASE INHIBITORS, BY TYPE

14.5.1.1. ACARBOSE

14.5.1.2. MIGLITOL

14.5.2 A-GLUCOSIDASE INHIBITORS, BY DRUG TYPE

14.5.2.1. GENERIC

14.5.2.2. BRANDED

14.5.2.2.1. PRECOSE

14.5.2.2.2. GLYSET

14.5.2.2.3. OTHERS (IF ANY)

14.6 INSULIN SECRETAGOGUES

14.6.1 SULFONYLUREAS

14.6.1.1. SULFONYLUREAS, BY TYPE

14.6.1.1.1. FIRST GENERATION

14.6.1.1.1.1 ACETOHEXAMIDE

14.6.1.1.1.2 CHLORPROPAMIDE

14.6.1.1.1.3 TOLAZAMIDE

14.6.1.1.1.4 TOLBUTAMIDE

14.6.1.1.2. SECOND GENERATION

14.6.1.1.2.1 GLIPIZIDE

14.6.1.1.2.2 GLYBURIDE

14.6.1.1.2.3 GLICLAZIDE

14.6.1.1.2.4 GLIMEPIRIDE

14.6.1.2. SULFONYLUREAS, BY DRUG TYPE

14.6.1.2.1. GENERIC

14.6.1.2.2. BRANDED

14.6.1.2.2.1 DIAMICRON

14.6.1.2.2.2 GLIBENESE

14.6.1.2.2.3 AMARYL

14.6.1.2.2.4 GLYNASE

14.6.1.2.2.5 OTHERS (IF ANY)

14.6.2 GLINIDES

14.6.2.1. GLINIDES, BY TYPE

14.6.2.1.1. REPAGLINIDE

14.6.2.1.2. NATEGLINIDE

14.6.2.2. GLINIDES, BY DRUG TYPE

14.6.2.2.1. GENERIC

14.6.2.2.2. BRANDED

14.6.2.2.2.1 PRANDIN

14.6.2.2.2.2 STARLIX

14.6.2.2.2.3 OTHERS (IF ANY)

14.7 SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) INHIBITORS

14.7.1 SGLT2 INHIBITORS, BY TYPE

14.7.1.1. CANAGLIFLOZIN

14.7.1.2. DAPAGLIFLOZIN

14.7.1.3. EMPAGLIFLOZIN

14.7.1.4. OTHERS (IF ANY)

14.7.2 SGLT2 INHIBITORS, BY DRUG TYPE

14.7.2.1. GENERIC

14.7.2.2. BRANDED

14.7.2.2.1. FORXIGO

14.7.2.2.2. INVOKANA

14.7.2.2.3. BRENZAVVY

14.7.2.2.4. JARDIANCE

14.7.2.2.5. STEGLATRO

14.7.2.2.6. OTHERS (IF ANY)

14.8 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS

14.9 OTHERS

14.9.1 COMBINATION DRUGS

14.9.1.1. COMBINATION DRUGS, BY TYPE

14.9.1.1.1. ALOGLIPTIN/METFORMIN

14.9.1.1.2. CANAGLIFLOZIN/METFORMIN

14.9.1.1.3. DAPAGLIFLOZIN/METFORMIN

14.9.1.1.4. DAPAGLIFLOZIN/METFORMIN/SAXAGLIPTIN

14.9.1.1.5. EMPAGLIFLOZIN/LINAGLIPTIN/METFORMIN

14.9.1.1.6. EMPAGLIFLOZIN/METFORMIN

14.9.1.1.7. ERTUGLIFLOZIN/METFORMIN

14.9.1.1.8. GLIPIZIDE/METFORMIN

14.9.1.1.9. GLYBURIDE/METFORMIN

14.9.1.1.10. LINAGLIPTIN/METFORMIN

14.9.1.1.11. METFORMIN/PIOGLITAZONE

14.9.1.1.12. METFORMIN/ROSIGLITAZONE

14.9.1.1.13. METFORMIN/REPAGLINIDE

14.9.1.1.14. OTHERS

14.9.1.2. COMBINATION DRUGS, BY DRUG TYPE

14.9.1.2.1. GENERIC

14.9.1.2.2. BRANDED

14.9.1.2.2.1 KAZANO

14.9.1.2.2.2 INVOKAMET

14.9.1.2.2.3 XIGDUO XR

14.9.1.2.2.4 QTERNMET XR

14.9.1.2.2.5 TRIJARDY XR

14.9.1.2.2.6 SYNJARDY

14.9.1.2.2.7 SEGLUROMET

14.9.1.2.2.8 METAGLIP

14.9.1.2.2.9 GLUCOVANCE

14.9.1.2.2.10 JENTADUETO

14.9.1.2.2.11 JENTADUETO XR

14.9.1.2.2.12 ACTOPLUS MET

14.9.1.2.2.13 PRANDIMET

14.9.1.2.2.14 AVANDAMET

14.9.1.2.2.15 KOMBIGLYZE XR

14.9.1.2.2.16 OTHERS

14.9.2 OTHERS (IF ANY)

15 GLOBAL ORAL ANTIDIABETIC DRUGS MARKET, BY DRUG TYPE

15.1 OVERVIEW

15.2 BRANDED

15.2.1 FORTAMET

15.2.2 GLUCOPHAGE

15.2.3 GLUCOPHAGE XR

15.2.4 GLUMETZA

15.2.5 RIOMET

15.2.6 FORXIGO

15.2.7 INVOKANA

15.2.8 BRENZAVVY

15.2.9 JARDIANCE

15.2.10 STEGLATRO

15.2.11 PRANDIN

15.2.12 STARLIX

15.2.13 DIAMICRON

15.2.14 GLIBENESE

15.2.15 AMARYL

15.2.16 GLYNASE

15.2.17 OTHERS

15.3 GENERIC

16 GLOBAL ORAL ANTIDIABETIC DRUGS MARKET, BY ACTIVITY

16.1 OVERVIEW

16.2 EXTENDED RELEASE

16.3 IMMEDIATE RELEASE

17 GLOBAL ORAL ANTIDIABETIC DRUGS MARKET, BY DIABETES TYPE

17.1 OVERVIEW

17.2 TYPE 1 DIABETES

17.3 TYPE 2 DIABETES

17.4 GESTATIONAL DIABETES

18 GLOBAL ORAL ANTIDIABETIC DRUGS MARKET, BY REGIMENS

18.1 OVERVIEW

18.2 MONTHERAPY

18.3 COMBINATION THERAPY

19 GLOBAL ORAL ANTIDIABETIC DRUGS MARKET, BY POPULATION TYPE

19.1 OVERVIEW

19.2 PEDIATRIC

19.2.1 BY GENDER

19.2.1.1. MALE

19.2.1.2. FEMALE

19.3 ADULTS

19.3.1 BY GENDER

19.3.1.1. MALE

19.3.1.2. FEMALE

19.4 GERIATRIC

19.4.1 BY GENDER

19.4.1.1. MALE

19.4.1.2. FEMALE

20 GLOBAL ORAL ANTIDIABETIC DRUGS MARKET, BY END USER

20.1 OVERVIEW

20.2 HOSPITALS

20.2.1 BY TYPE

20.2.1.1. PRIVATE

20.2.1.1.1. BY TIER

20.2.1.1.1.1 TIER I

20.2.1.1.1.2 TIER II

20.2.1.1.1.3 TIER III

20.2.1.2. PUBLIC

20.2.1.2.1. BY TIER

20.2.1.2.1.1 TIER I

20.2.1.2.1.2 TIER II

20.2.1.2.1.3 TIER III

20.3 HOME HEALTHCARE

20.4 SPECIALTY CENTERS

20.5 DIABETES CARE CENTERS

20.6 AMBULATORY CENTERS

20.7 OTHERS

21 GLOBAL ORAL ANTIDIABETIC DRUGS MARKET, BY DISTRIBUTION CHANNEL

21.1 OVERVIEW

21.2 DIRECT TENDER

21.3 RETAIL SALES

21.3.1 HOSPITAL PHARMACY

21.3.2 RETAIL PHARMACY

21.3.3 ONLINE PHARMACY

21.4 OTHERS

22 GLOBAL ORAL ANTIDIABETIC DRUGS MARKET, SWOT AND DBMR ANALYSIS

23 GLOBAL ORAL ANTIDIABETIC DRUGS MARKET, COMPANY LANDSCAPE

23.1 COMPANY SHARE ANALYSIS: GLOBAL

23.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

23.3 COMPANY SHARE ANALYSIS: EUROPE

23.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

23.5 MERGERS & ACQUISITIONS

23.6 NEW PRODUCT DEVELOPMENT & APPROVALS

23.7 EXPANSIONS

23.8 REGULATORY CHANGES

23.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS

24 GLOBAL ORAL ANTIDIABETIC DRUGS MARKET, BY REGION

GLOBAL ORAL ANTIDIABETIC DRUGS MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)

24.1 NORTH AMERICA

24.1.1 U.S.

24.1.2 CANADA

24.1.3 MEXICO

24.2 EUROPE

24.2.1 GERMANY

24.2.2 U.K.

24.2.3 ITALY

24.2.4 FRANCE

24.2.5 SPAIN

24.2.6 RUSSIA

24.2.7 SWITZERLAND

24.2.8 TURKEY

24.2.9 BELGIUM

24.2.10 NETHERLANDS

24.2.11 DENMARK

24.2.12 SWEDEN

24.2.13 POLAND

24.2.14 NORWAY

24.2.15 FINLAND

24.2.16 REST OF EUROPE

24.3 ASIA-PACIFIC

24.3.1 JAPAN

24.3.2 CHINA

24.3.3 SOUTH KOREA

24.3.4 INDIA

24.3.5 SINGAPORE

24.3.6 THAILAND

24.3.7 INDONESIA

24.3.8 MALAYSIA

24.3.9 PHILIPPINES

24.3.10 AUSTRALIA

24.3.11 NEW ZEALAND

24.3.12 VIETNAM

24.3.13 TAIWAN

24.3.14 REST OF ASIA-PACIFIC

24.4 SOUTH AMERICA

24.4.1 BRAZIL

24.4.2 ARGENTINA

24.4.3 REST OF SOUTH AMERICA

24.5 MIDDLE EAST AND AFRICA

24.5.1 SOUTH AFRICA

24.5.2 EGYPT

24.5.3 BAHRAIN

24.5.4 UNITED ARAB EMIRATES

24.5.5 KUWAIT

24.5.6 OMAN

24.5.7 QATAR

24.5.8 SAUDI ARABIA

24.5.9 REST OF MEA

24.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES

25 GLOBAL ORAL ANTIDIABETIC DRUGS MARKET, COMPANY PROFILE

25.1 PFIZER INC.

25.1.1 COMPANY OVERVIEW

25.1.2 REVENUE ANALYSIS

25.1.3 GEOGRAPHIC PRESENCE

25.1.4 PRODUCT PORTFOLIO

25.1.5 RECENT DEVELOPMENTS

25.2 NOVARTIS

25.2.1 COMPANY OVERVIEW

25.2.2 REVENUE ANALYSIS

25.2.3 GEOGRAPHIC PRESENCE

25.2.4 PRODUCT PORTFOLIO

25.2.5 RECENT DEVELOPMENTS

25.3 TEVA PHARMACEUTICALS USA, INC.

25.3.1 COMPANY OVERVIEW

25.3.2 REVENUE ANALYSIS

25.3.3 GEOGRAPHIC PRESENCE

25.3.4 PRODUCT PORTFOLIO

25.3.5 RECENT DEVELOPMENTS

25.4 ASTRAZENECA

25.4.1 COMPANY OVERVIEW

25.4.2 REVENUE ANALYSIS

25.4.3 GEOGRAPHIC PRESENCE

25.4.4 PRODUCT PORTFOLIO

25.4.5 RECENT DEVELOPMENTS

25.5 BAYER AG

25.5.1 COMPANY OVERVIEW

25.5.2 REVENUE ANALYSIS

25.5.3 GEOGRAPHIC PRESENCE

25.5.4 PRODUCT PORTFOLIO

25.5.5 RECENT DEVELOPMENTS

25.6 SANOFI

25.6.1 COMPANY OVERVIEW

25.6.2 REVENUE ANALYSIS

25.6.3 GEOGRAPHIC PRESENCE

25.6.4 PRODUCT PORTFOLIO

25.6.5 RECENT DEVELOPMENTS

25.7 ASTELLAS PHARMA INC.

25.7.1 COMPANY OVERVIEW

25.7.2 REVENUE ANALYSIS

25.7.3 GEOGRAPHIC PRESENCE

25.7.4 PRODUCT PORTFOLIO

25.7.5 RECENT DEVELOPMENTS

25.8 JOHNSON & JOHNSON HEALTH CARE SYSTEMS INC.

25.8.1 COMPANY OVERVIEW

25.8.2 REVENUE ANALYSIS

25.8.3 GEOGRAPHIC PRESENCE

25.8.4 PRODUCT PORTFOLIO

25.8.5 RECENT DEVELOPMENTS

25.9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH

25.9.1 COMPANY OVERVIEW

25.9.2 REVENUE ANALYSIS

25.9.3 GEOGRAPHIC PRESENCE

25.9.4 PRODUCT PORTFOLIO

25.9.5 RECENT DEVELOPMENTS

25.1 NOVO NORDISK A/S

25.10.1 COMPANY OVERVIEW

25.10.2 REVENUE ANALYSIS

25.10.3 GEOGRAPHIC PRESENCE

25.10.4 PRODUCT PORTFOLIO

25.10.5 RECENT DEVELOPMENTS

25.11 MERCK & CO., INC.

25.11.1 COMPANY OVERVIEW

25.11.2 REVENUE ANALYSIS

25.11.3 GEOGRAPHIC PRESENCE

25.11.4 PRODUCT PORTFOLIO

25.11.5 RECENT DEVELOPMENTS

25.12 GSK PLC.

25.12.1 COMPANY OVERVIEW

25.12.2 REVENUE ANALYSIS

25.12.3 GEOGRAPHIC PRESENCE

25.12.4 PRODUCT PORTFOLIO

25.12.5 RECENT DEVELOPMENTS

25.13 AJANTA PHARMAC INC.

25.13.1 COMPANY OVERVIEW

25.13.2 REVENUE ANALYSIS

25.13.3 GEOGRAPHIC PRESENCE

25.13.4 PRODUCT PORTFOLIO

25.13.5 RECENT DEVELOPMENTS

25.14 LUPIN

25.14.1 COMPANY OVERVIEW

25.14.2 REVENUE ANALYSIS

25.14.3 GEOGRAPHIC PRESENCE

25.14.4 PRODUCT PORTFOLIO

25.14.5 RECENT DEVELOPMENTS

25.15 AMNEAL PHARMACEUTICALS INC.

25.15.1 COMPANY OVERVIEW

25.15.2 REVENUE ANALYSIS

25.15.3 GEOGRAPHIC PRESENCE

25.15.4 PRODUCT PORTFOLIO

25.15.5 RECENT DEVELOPMENTS

25.16 LES LABORATORIES SERVIER

25.16.1 COMPANY OVERVIEW

25.16.2 REVENUE ANALYSIS

25.16.3 GEOGRAPHIC PRESENCE

25.16.4 PRODUCT PORTFOLIO

25.16.5 RECENT DEVELOPMENTS

25.17 ADVACARE PHARMA

25.17.1 COMPANY OVERVIEW

25.17.2 REVENUE ANALYSIS

25.17.3 GEOGRAPHIC PRESENCE

25.17.4 PRODUCT PORTFOLIO

25.17.5 RECENT DEVELOPMENTS

25.18 WELLONA PHARMA

25.18.1 COMPANY OVERVIEW

25.18.2 REVENUE ANALYSIS

25.18.3 GEOGRAPHIC PRESENCE

25.18.4 PRODUCT PORTFOLIO

25.18.5 RECENT DEVELOPMENTS

25.19 THERACOSBIO, LLC

25.19.1 COMPANY OVERVIEW

25.19.2 REVENUE ANALYSIS

25.19.3 GEOGRAPHIC PRESENCE

25.19.4 PRODUCT PORTFOLIO

25.19.5 RECENT DEVELOPMENTS

25.2 TAKEDA PHARMACEUTICAL COMPANY LIMITED

25.20.1 COMPANY OVERVIEW

25.20.2 REVENUE ANALYSIS

25.20.3 GEOGRAPHIC PRESENCE

25.20.4 PRODUCT PORTFOLIO

25.20.5 RECENT DEVELOPMENTS

26 RELATED REPORTS

27 CONCLUSION

28 QUESTIONNAIRE

29 ABOUT DATA BRIDGE MARKET RESEARCH